PPAR Research

PPARs: A Double-Edged Sword in Cancer Therapy?


Publishing date
01 Sep 2008
Status
Published
Submission deadline
01 Mar 2008

PPARs: A Double-Edged Sword in Cancer Therapy?

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 9469261
  • - Retraction

Retracted: Rosiglitazone Suppresses the Growth and Invasiveness of SGC-7901 Gastric Cancer Cells and Angiogenesis In Vitro via PPARγ Dependent and Independent Mechanisms

PPAR Research
  • Special Issue
  • - Volume 2008
  • - Article ID 350351
  • - Editorial

PPARs: A Double-Edged Sword in Cancer Therapy?

Dipak Panigrahy | Arja Kaipainen | ... | Sui Huang
  • Special Issue
  • - Volume 2008
  • - Article ID 750238
  • - Review Article

Combination Therapy of PPAR 𝛾 Ligands and Inhibitors of Arachidonic Acid in Lung Cancer

Jordi Tauler | James L. Mulshine
  • Special Issue
  • - Volume 2008
  • - Article ID 286249
  • - Review Article

The Role of NF- B in PPAR -Mediated Hepatocarcinogenesis

Howard P. Glauert | Karen Calfee-Mason | ... | Brett T. Spear
  • Special Issue
  • - Volume 2008
  • - Article ID 827096
  • - Review Article

The Role of PPAR 𝛾 Receptors and Leukotriene B 4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer

Thomas E. Adrian | Rene Hennig | ... | Xianzhong Ding
  • Special Issue
  • - Volume 2008
  • - Article ID 134059
  • - Review Article

PPARs Mediate Lipid Signaling in Inflammation and Cancer

Liliane Michalik | Walter Wahli
  • Special Issue
  • - Volume 2008
  • - Article ID 159415
  • - Review Article

Clinical Use of PPAR Ligands in Cancer

Jennifer L. Hatton | Lisa D. Yee
  • Special Issue
  • - Volume 2008
  • - Article ID 932632
  • - Review Article

PPAR 𝛾 , PTEN, and the Fight against Cancer

Rosemary E. Teresi | Kristin A. Waite
  • Special Issue
  • - Volume 2008
  • - Article ID 904251
  • - Review Article

The Role of PPARs in the Endothelium: Implications for Cancer Therapy

David Bishop-Bailey | Karen E. Swales
  • Special Issue
  • - Volume 2008
  • - Article ID 945275
  • - Review Article

PPAR 𝛾 and Agonists against Cancer: Rational Design of Complementation Treatments

Dorina Veliceasa | Frank Thilo Schulze-Hoëpfner | Olga V. Volpert
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore7.100
Impact Factor2.953
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.